Ricardo is a natural-born serial entrepreneur. He sold his first company at the age of 22. This led to the creation and development of various companies with a strong bent towards innovation.

The cancer diagnosis of his son motivated him to create Oncoheroes Biosciences and the Richi Childhood Cancer Foundation, a 501 (c) (3) non profit organization established in the US and with links around the world.

Cesare has more than 20 years of experience in the drug development field.

Following the death of his first daughter Laura to cancer, Cesare set up aPODD Foundation, a London-based charity focused on accelerating paediatric oncology drug development.

Cesare holds an MSc in Applied Molecular Biology and a PhD in Neurosciences from UCL, University of London, as well as an MBA from the Central European University, Budapest.

Michel was Senior Director at Janssen (Johnson & Johnson; Beerse. Belgium), where he was involved in early clinical development of novel oncology drug candidates, scientific licensing and strategic partnering.

Prior to this, Michel served as Associate Research Fellow at Rhone-Poulenc Rorer (Paris. France) and was postdoctoral fellow at The Johns Hopkins University (Baltimore, MD. USA) in the department of Biological Chemistry.

Eva has more than 17 years of experience in academic and industrial biomedical research. She was head of several drug discovery departments and strategy at Ferrer Group.

Eva is a member of the Business Advisory Board of the Institute of Research in Biomedicine of Barcelona (IRB Barcelona) and an advisor for European Collaborative Research Projects.

Evie Mengou is a seasoned regulatory affairs professional, with over 20 years’ experience in pharmaceutical drug development spanning several therapeutic areas, involving small molecules and biologics.

Following the introduction of Paediatric Regulation in Europe, she has been involved in leading the preparation, negotiation and execution of paediatric investigation plans and paediatric clinical trials.

Dawn is a CMC and regulatory compliance professional with 20 years of international experience within the pharmaceutical industry, developing the CMC control strategy for more than 50 clinical drug candidates and has contributed to the development of several commercially approved drugs. She has worked with regulatory health authorities including FDA and Europe National Competent Authorities and across multiple indications.

Jonathan has significant legal, biotech, non-profit/for profit organizational, managerial and advocacy experience. Having spent over 19 years in the practice of law, 16 of which were as a full-time litigator in Washington, DC & Maryland, he transitioned from legal practice and the law firm that he co-founded following the loss of his daughter Alexis to pediatric brain cancer in 2011. He was an original founding member of the DIPG Collaborative.

Berta Martí Fuster is a biomedical researcher by background with strong communication skills. She holds a bachelor of science in Physics (2007) and a Ph.D. in Biomedicine (2013) from the University of Barcelona. In September of 2014, she moved to Boston where she joined the Madrid-MIT M+Visión consortium. As a M+Visión fellow, she was taught how to identify unmet healthcare needs through the IDEA3 process.